Uterine corpus cancer and ovarian cancer
Conditions
Interventions
Dexamethasone sodium phosphate: Administer 13.2 mg via intravenous infusion on the first day of chemotherapy. Dexamethasone: Administer 4 mg orally twice a day (8 mg per day). Administer orally for
Sponsors
Dokkyo Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patients aged 20 years or older and 75 years or younger. 2) Patients with a Performance Status (ECOG scale) of 0-1. 3) Patients who have not received prior radiation therapy to the pelvic region. 4) Patients who have provided written informed consent of their own free will after receiving a thorough explanation of the study.
Exclusion criteria
Exclusion criteria: 1) Patients with diabetes mellitus requiring insulin treatment. 2) Patients taking medications for osteoporosis. 3) Patients with confirmed osteoporosis requiring treatment. 4) Patients with a young adult mean (YAM) value of 70% or less. 5) Patients with mental disorders or dementia. 6) Patients with any contraindication to dexamethasone treatment. 7) Patients deemed inappropriate for participation in the present study by the principal investigator or co-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate changes in bone mineral density (measured using DEXA) and glucose tolerance before and after chemotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To investigate changes in bone metabolism markers (serum NTX, BAP, and TRACP5b) before and after chemotherapy. 2) To investigate changes in glucose tolerance (HOMA-R) before and after chemotherapy. For patients taking medications for diabetes, changes in these medications before and after chemotherapy will be examined. 3) To investigate the association between total steroid dose and changes in bone density and glucose tolerance. | — |
Countries
Japan
Contacts
Public ContactYoshimasa KAWARAI
Dokkyo Medical University Department of Obstetrics and Gynecology
Outcome results
None listed